Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905601 | 1.00 | KDM4E (0.52) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL6806101 | 0.90 | KDM4E (0.49) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL6806097 | 0.90 | KDM4E (0.49) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL10414536 | 0.87 | FGF23 (0.56) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL6386356 | 0.87 | NAPRT (0.51) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL10414535 | 0.87 | FGF23 (0.56) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL6386359 | 0.87 | NAPRT (0.51) | KDM4ETDP1MAPTALDH1A1ALOX15 | |
| SCHEMBL4469339 | 0.87 | SIRT2 (0.50) | KDM4ETDP1MAPTALDH1A1LMNA | |
| SCHEMBL4469336 | 0.87 | SIRT2 (0.50) | KDM4ETDP1MAPTALDH1A1LMNA | |
| SCHEMBL9000477 | 0.86 | KDM4E (0.55) | KDM4ETDP1MAPTALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101302192-B | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC | 2014-01-22 | — | — | CN | disclosed |
| EP-1335726-B1 | MODIFIED PRODRUG FORMS OF AP | NANOTHERAPEUTICS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1335726-A4 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| CN-101302192-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | CN | disclosed |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-6911460-B2 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1335726-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | Vion Pharmaceuticals, Inc. (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | disclosed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6458816-B1 | ANTICANCER AGENTS | VION PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030424-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| CN-1256687-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC (US) | 2000-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | KDM4E 1927/4885TDP1 1335/4885MAPT 3684/4885 |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | KDM4E 4331/4885TDP1 1726/4885MAPT 4855/4885 |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | KDM4E 1927/4885TDP1 1335/4885MAPT 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.